Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.) Patents (Class 424/93.2)
  • Patent number: 10266834
    Abstract: The present invention provides compositions and methods for the production and delivery of recombinant double-stranded RNA molecules (dsRNA) encoding heterologous proteins, which can be useful for various therapeutic purposes as well as for the production of desired proteins. The compositions contain engineered double-stranded RNA particles (dsRPs) that can contain a double-stranded RNA molecule that can be a genome or portion of a genome, which can be enclosed in a capsid or coat protein. The dsRNA molecule also comprises an RNA sub-sequence that encodes a heterologous protein. The dsRPs can be derived from wild-type viral organisms. The delivery of the dsRPs (or DNA or RNA molecules) of the invention to an organism provides for therapeutic benefits as well as for the production of desired proteins.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: April 23, 2019
    Assignee: Synthetic Genomics, Inc.
    Inventors: Robert C. Brown, Kurt I. Kamrud
  • Patent number: 10266847
    Abstract: Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: April 23, 2019
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Pin Wang, Lili Yang, David Baltimore
  • Patent number: 10265357
    Abstract: Embodiments of the present invention relate to compositions and methods for producing recombinant VSV viruses. In accordance with these embodiments, viral vectors can include a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV. Other embodiments relate to cells for producing a LCMV-GP-pseudotyped VSV vectors. Embodiments also relate to the use of the vectors and cells as part of a pharmaceutical composition for the treatment of solid tumors.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: April 23, 2019
    Assignee: VIRATHERAPEUTICS GMBH
    Inventors: Dorothee Von Laer, Tsanan Heimann
  • Patent number: 10266846
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 23, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10253089
    Abstract: A delivery system that includes a recombinantly synthesized protein polymer with protease cleavage sites such as matrix metalloproteinase responsive sequences engineered within the protein polymer. The system may be used to treat cancer, wounds, or pathological conditions in other tissues that express excess protease relative to healthy tissue.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: April 9, 2019
    Assignee: University of Utah Research Foundation
    Inventors: Hamidreza Ghandehari, Joseph Cappello, Jordan Frandsen, Joshua Gustafson, Khaled Greish, Robert Andrew Price
  • Patent number: 10238695
    Abstract: Composition containing a microorganism, preferably an Archaea, expressing a TMA methyltransferase and a TMA methyl group acceptor corrinoid protein, capable of metabolizing trimethylamine (TMA) in the presence of hydrogen in a human cavity, such as the intestine or the vagina, for use as a medicament for treating, reducing or eliminating TMA at the level of the human cavity. In addition, a composition containing a TMA methyltransferase and a TMA methyl group acceptor corrinoid protein. These compositions are of use for treating trimethylaminuria, for treating vaginal fluids in the case of bacterial vaginosis and for reducing or eliminating odours due to TMA. These compositions are also of use for reducing the level of plasma TMAO, for preventing the formation of atheroma plaques and/or for preventing cardiovascular diseases.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 26, 2019
    Assignee: UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Jean-François Brugere, Guillaume Borrel, Paul William O'Toole, Corinne Malpuech-Brugere, Monique Alric
  • Patent number: 10232002
    Abstract: Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides an oncolytic virus capable of killing target cells, such as tumor cells. In various embodiments presented herein, the oncolytic viruses described herein are suitable for treatment of several types of cancer, including glioblastoma.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: March 19, 2019
    Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, OHIO STATE INNOVATION FOUNDATION
    Inventors: Hiroshi Nakashima, Ennio Antonio Chiocca
  • Patent number: 10232053
    Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 19, 2019
    Assignee: Trieza Therapeutics, Inc.
    Inventors: Daniel Hicklin, Kenneth Nelson Wills, Cynthia Seidel-Dugan, William Winston, Philipp Steiner
  • Patent number: 10202618
    Abstract: In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid or gene in a cell or in vivo; and administering or delivering the paracrine polypeptide -encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: February 12, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: H. Kirk Hammond, Mei Hua Gao
  • Patent number: 10201575
    Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and a plurality of copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells, and a deletion of the internal repeat (joint) region in the HSV genome comprising one copy of the ICP0, ICP34.5, LAT, and ICP4 genes and the ICP47 promoter. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: February 12, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
  • Patent number: 10188132
    Abstract: The present invention is concerned with providing refined plant isolates that can be used as starting materials for the production of functional food ingredients, such as taste enhancers, through an isolation process that employs ion exclusion chromatography. More particularly, the present invention provides a refined plant isolate comprising at least 30% by weight of dry matter of water soluble plant components selected from fructose, glucose, proteinaceous matter of plant origin, acids and potassium, said isolate further being characterized in that at a concentration of 40° Brix the isolate: •contains at least 0.3 wt % of glutamate; •contains at least 500 ppm of K+; •contains less than 300 ppm of Ca2+; •contains less than 700 ppm of Mg2+; •contains less than 1 wt. % of components capable of passing an ultra filtration membrane having a molecular weight cut off of 250 kDa; wherein the concentration ratio ([Ca2+]+[Mg2+])/[K+] does not exceed 5:100, each of said cation concentrations being expressed in ppm.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: January 29, 2019
    Assignee: Conopco Inc.
    Inventors: Nikolaos Mavroudis, Marco Giuseppe Mazzotti
  • Patent number: 10189888
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 29, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • Patent number: 10179153
    Abstract: The invention relates to products and compositions that may be beneficial in animal husbandry. Said products and compositions comprise microorganisms, such as bacteria, and probiotic bacteria in particular. Thus, provided herein are microbial strains, as well as selection criteria which will enable the skilled reader to find further strains useful in the present invention. The strains, as well as compositions comprising the same, may be administered to animals, farmed animals such as swine in particular. The administration may occur in the first days of life. By administration of the products or compositions of the inventions animal growth can. be promoted and animal weight can be increased. Infections may also be prevented or treated by said compounds or compositions.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: January 15, 2019
    Assignees: Universidad De Leon, Aquilon CYL S.L.
    Inventors: Pedro Miguel Rubio Nistal, Ana Maria Carvajal Urueña, Marta García Díez
  • Patent number: 10167454
    Abstract: Viral vectors comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis cirrhosis in OTCD patients by administering hOTC.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: January 1, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Lili Wang, James M. Wilson
  • Patent number: 10167323
    Abstract: Improved compositions and methods for controlling pests are disclosed. In particular, nucleic acid molecules encoding novel engineered Cry1Ba (eCry1Ba) proteins having improved toxicity to lepidopteran insect pests are provided. By substituting at least one amino acid in domain I of a Cry1Ba protein an engineered Cry1Ba protein having substantially altered insecticidal properties is designed. Further, methods of making and using the ecry1Ba nucleic acid sequences, for example in transgenic plants to express eCry1B proteins to confer protection from insect damage are disclosed.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: January 1, 2019
    Assignee: Syngenta Participations AG
    Inventors: Yan Gao, Jared Conville, Jeng Shong Chen
  • Patent number: 10159753
    Abstract: The present invention relates to vectors containing liver-specific regulatory sequences and codon-optimized factor IX or factor VIII genes, methods employing these vectors and uses of these vectors. Expression cassettes and vectors containing these liver-specific regulatory elements and codon-optimized factor IX or factor VIII genes are also disclosed. The present invention is particularly useful for applications using gene therapy, in particular for the treatment of hemophilia A and B.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: December 25, 2018
    Assignee: Vrije Universiteit Brussel
    Inventors: Thierry Vandendriessche, Marinee Chuah
  • Patent number: 10149914
    Abstract: Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 11, 2018
    Assignees: VIB VZW, Life Sciences Research Partners VZW, Universiteit Gent
    Inventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Patent number: 10149873
    Abstract: Recombinant vectors comprise simian adenovirus A1321 (SAdV-A1321), SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1321, SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: December 11, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Soumitra Roy, James M. Wilson
  • Patent number: 10138479
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: November 27, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Patent number: 10124028
    Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: November 13, 2018
    Assignee: PSIOXUS THERAPEUTICS LIMITED
    Inventors: Brian Robert Champion, Alice Claire Noel Brown
  • Patent number: 10113147
    Abstract: Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: October 30, 2018
    Assignee: AdipoSeeds, Inc.
    Inventors: Yumiko Matsubara, Takeru Zama, Yasuo Ikeda, Yukako Uruga, Toshio Suda, Sahoko Matsuoka
  • Patent number: 10106781
    Abstract: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: October 23, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., Washington University
    Inventors: Dan H. Barouch, Herbert Virgin, IV, Peter Abbink
  • Patent number: 10106860
    Abstract: The present invention relates to a kit for simultaneous diagnosis of viral respiratory diseases. To be more specific, the present invention is directed to a method for diagnosing viral respiratory diseases by detecting the genes specific to the respiratory disease-causing virus, a primer set for diagnosing the viral respiratory diseases used in the diagnosis method, a composition for simultaneous diagnosis of viral respiratory diseases, comprising the primer set, and a kit for simultaneous diagnosis of viral respiratory diseases, comprising the composition. When the primer set of the present invention for diagnosing the viral respiratory diseases is used, 14 different types of respiratory viruses can be simultaneously detected only with one reaction through real-time multiplex reverse transcription (RT)-PCR, and the onset of respiratory diseases caused by these viruses can be diagnosed. Thus, the primer set of the present invention can be widely used for prompt diagnosis and treatment of respiratory diseases.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: October 23, 2018
    Assignee: LG Chem, LTD.
    Inventors: Eun Joo Yoo, Young Suk Park, Ji Eun Heo, Jin Seok Kang
  • Patent number: 10086016
    Abstract: The present invention is related to a pharmaceutical composition comprising cells committed to the generation of heart tissue and at least one pharmaceutically acceptable excipient produced according to internationally recognized standards for pharmaceutical product manufacture, a process for the manufacture of such a pharmaceutical composition and a kit for the administration of said pharmaceutical composition which comprises a container containing said pharmaceutical composition.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 2, 2018
    Assignee: CELYAD S.A.
    Inventors: Vinciane Gaussin, Roland Gordon-Beresford, Christian Homsy
  • Patent number: 10086012
    Abstract: Provided herein are devices and methods for reversibly controlling memory function in living non-human animals. Some variations of methods for affecting memory function comprise temporarily inhibiting neurons of the hippocampus (e.g., neurons of the dorsal CA1 field of the hippocampus) during the acquisition or retrieval of a memory. Alternatively or additionally, methods for reversibly affecting memory function comprise inhibiting neurons of the amygdala (e.g. basolateral amygdala) and/or neurons of the cingulate cortex (e.g., anterior cingulated cortex). Methods for disrupting the formation and recall of memories by inhibiting excitatory neurons expressing light-activated proteins are disclosed herein. One or more methods for reversibly affecting memory function described herein can be used to evaluate the effectiveness of pharmacological agents in treating PTSD and/or various memory disorders.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: October 2, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Inbal Goshen
  • Patent number: 10071126
    Abstract: An object of the present invention is to provide a conditionally replicating adenovirus having a strong anticancer effect. A conditionally replicating adenovirus to replicate specifically in a cancer cell and express REIC protein or REIC C domain protein, wherein the conditionally replicating adenovirus is obtained by inserting full-length REIC DNA or REIC C domain DNA into a conditionally replicating adenovirus comprising an ITR (inverted terminal repeat) sequence of an adenovirus type 5 genome and insertion of an HRE sequence, an hTERT promoter, a decorin-encoding DNA, and a DNA encoding a peptide comprising an RGD sequence.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: September 11, 2018
    Assignees: National University Corporation Okayama University, Momotaro-Gene Inc., Industry-University Cooperation Foundation Hanyang University
    Inventors: Hiromi Kumon, Yasutomo Nasu, Masami Watanabe, Chae Ok Yun
  • Patent number: 10066240
    Abstract: There are disclosed nucleic acid vectors for use in both gram positive and gram negative bacteria. In embodiments the vectors comprise a prokaryotic expression cassette and in embodiments comprise a eukaryotic expression cassette. In embodiments the vectors encode a hybrid protein comprising a DNA binding domain, a CPP domain and a signal sequence.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: September 4, 2018
    Assignee: Symvivo Corporation
    Inventors: Herbert Alexander Graves, Mark Andrew Fox, Sheetal Raithatha, Umesh Ramachandran
  • Patent number: 10066223
    Abstract: The present invention provides for a novel recombinant or isolated nucleic acid useful for integrating or being maintained in an Archaea or acidophilic hyperthermophilic eubacteria. The nucleic acid encodes a nucleotide sequence that is capable of stably integrating into the chromosome of a host cell, or being maintained as an extrachromosomal element in a host cell, that is an Archea, and a nucleotide sequence of interest. The present invention also provides for an Archaea host cell comprising the nucleic acid stably integrated into the chromosome or maintained episomally in the host cell, and a method of expressing the nucleotide sequence of interest in the host cell and/or directing glycosylation, multimerization, and/or membrane association or integration.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: September 4, 2018
    Assignee: The Regents of the University of California
    Inventors: Steven M. Yannone, Adam Barnebey
  • Patent number: 10059940
    Abstract: Provided herein are chemically ligated guide RNA oligonucleotides (lgRNA) which comprise two functional RNA modules (crgRNA and tracrgRNA) joined by non-nucleotide chemical linkers (nNt-linker), their complexes with CRISPR-Cas9, preparation methods of Cas9-lgRNA complexes, and their uses for treatments of viral infections in humans. Also disclosed are processes and methods for preparation of these compounds.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: August 28, 2018
    Inventor: Minghong Zhong
  • Patent number: 10058591
    Abstract: The present invention relates to a combination of a parvovirus and a cytokine, preferably IFNy, for use in treating pancreatic cancer, in particular a terminal stage of this disease.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: August 28, 2018
    Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet Heidelberg
    Inventors: Zahari Raykov, Svitlana Grekova, Laurent Daeffler, Jean Rommelaere, Marc Aprahamian, Nathalia Giese
  • Patent number: 10060933
    Abstract: The present invention provides methods and uses for the diagnostic of a subject predisposed or suspected of developing a neurodegenerative disease or suffering from a neurodegenerative disease. The present invention also relates to methods and uses for identifying candidate compounds and to compounds for treating neurodegenerative disease. The present invention also relates to an animal model for neurodegenerative disease.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: August 28, 2018
    Assignee: UNIVERSITE LAVAL
    Inventors: Jean-Pierre Julien, Vivek Swarup
  • Patent number: 10058624
    Abstract: Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 28, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Christopher B. Doering, H. Trent Spencer, Harrison C. Brown
  • Patent number: 10052376
    Abstract: The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: August 21, 2018
    Assignee: ALTERNATIVE INNOVATIVE TECHNOLOGIES LLC
    Inventors: Sergey B. Onikienko, Alexander V. Zemlyanoi, Boris A. Margulis, Irina V. Guzhova, Anna A. Pimenova
  • Patent number: 10047347
    Abstract: The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E1B gene product, expressed from the E1B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E1B-156R isoform is increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells while sparing normal cells.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: August 14, 2018
    Assignee: Ixogen Ltd.
    Inventor: Hans Daniel Öberg
  • Patent number: 10034938
    Abstract: The invention relates to methods of treating melanoma using a herpes simplex virus in combination with an immune checkpoint inhibitor.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: July 31, 2018
    Assignee: Amgen Inc.
    Inventors: Ari Vanderwalde, Mohamed Shabooti
  • Patent number: 10036060
    Abstract: The present invention provides methods for the amplification of nucleic acid molecules. Methods for amplifying target polynucleotides, including mRNA, using oligonucleotides, DNA and RNA polymerases are provided. The invention further provides compositions and kits for practicing the methods, as well as methods which use the amplification products.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: July 31, 2018
    Assignee: Life Technologies Corporation
    Inventors: Mark G. Erlander, Ranelle C. Salunga
  • Patent number: 10017765
    Abstract: The disclosure provides methods of treating polyglutamine diseases, e.g., spinocerebellar ataxia Type 6, in a subject, comprising administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject. Also provided herein are the IRES inhibitors, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: July 10, 2018
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Christopher M. Gomez, Xiaofei Du
  • Patent number: 10016470
    Abstract: The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: July 10, 2018
    Assignee: DNATRIX, INC.
    Inventors: Ramon Alemany Bonastre, Juan Jose Rojas Exposito, Manel Maria Cascallo Piqueras
  • Patent number: 10010498
    Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: July 3, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg
  • Patent number: 10006049
    Abstract: The present invention provides novel mRNA elements capable of forming hairpin, double-stranded RNA structures independent of other non-coding RNAs. These mRNAs are stably expressed, lack polyadenylation tails, and allow minimal protein translation except when in the presence of specific proteins. Also provided, are compositions and kits comprising the mRNA element, as well as methods for its use in the regulation of protein translation. Advantageously, the disclosed elements represent a novel tool useful in regulating the expression of a wide variety of proteins of interest.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: June 26, 2018
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Chen Ling, Arun Srivastava
  • Patent number: 10006048
    Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 26, 2018
    Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: Michael Wayne Graham, Robert Norman Rice
  • Patent number: 10000557
    Abstract: The present invention generally relates to methods of generating antibodies against a species of pathogen that involve identifying the pathogen that is most genetically representative of member of pathogen species and using the identified pathogen to generate an antibody.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: June 19, 2018
    Assignee: DNAE Group Holdings Limited
    Inventors: Colin Dykes, Sergey A. Dryga, Lisa-Jo Ann Clarizia, Eddie W. Adams, Meghan Norvell
  • Patent number: 9987371
    Abstract: A pharmaceutical composition comprising a peptide-polynucleotide complex, and methods of use thereof.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: June 5, 2018
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Samuel A. Wickline, Kirk Hou
  • Patent number: 9987315
    Abstract: The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: June 5, 2018
    Assignee: The University of Western Ontario
    Inventors: Grant McFadden, John Barrett, Marianne Stanford
  • Patent number: 9981010
    Abstract: A method and system to induce bone growth by locally delivering bone morphogenetic proteins (BMPs) to the target location for a prolonged period without invasive procedures are disclosed. The new bone growth is induced by delivering cells producing BMPs from transduced viral vectors to the target cite. In various embodiments, the cells are encapsulated in hydrogel microspheres that are non-degradable or degradable by enzymes produced during the bone formation process. Various embodiments may be used to induce spinal fusion or repair critical bone defects.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: May 29, 2018
    Assignees: Baylor College of Medicine, William Marsh Rice University
    Inventors: Alan R. Davis, Elizabeth A. Davis, Kevin Moran, Ronke M. Olabisi, Jennifer L. West, Christy Franco
  • Patent number: 9976116
    Abstract: The present invention relates to an expression system or a recombinant cell comprising one or more nucleic acid constructs, wherein the one or more nucleic acid constructs comprise: (i) a first gene encoding for one or more protein(s) that activate a quorum sensing system; and (ii) a second gene encoding for one or more lytic protein(s) capable of forming a lesion in a host cell's membrane; wherein the first gene is under control of a first promoter and the second gene is under control of a second promoter, wherein the first promoter controlling the first gene is a carbon starvation-induced promoter and the second promoter is a quorum sensing system promoter induced by the quorum sensing system activated by one or more protein(s) encoded by the first gene as well as recombinant cells hosting such an expression system. Further encompassed is the use of the expression systems and cells of the invention for the expression of gene products of interest and the respective methods of use.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: May 22, 2018
    Assignee: Nanyang Technological University
    Inventors: Matthew Wook Chang, Tat Ming Samuel Lo, Mui Hua Tan
  • Patent number: 9957287
    Abstract: The present disclosure is directed to novel methods of treating type-1 or type-2 diabetes by inactivating TLR2 and TLR4 genes together in cells capable of producing insulin and/or regenerating ? cells, and providing the cells to a subject in need thereof.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: May 1, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Ling Qi, Shengyi Sun, Yewei Ji
  • Patent number: 9951329
    Abstract: The present invention relates to compositions of virus-like particles for the introduction of RNA-interference (RNAi-) inducing molecules into eukaryotic cells and methods for the cell type-specific transduction of a plurality of eukaryotic cells with RNAi-inducing molecules. The present invention furthermore relates to methods for a diagnosis, prevention and/or treatment of diseases or disease states associated with an increased expression rate of at least one endogenous gene, and/or with the undesired expression of at least one endogenous gene and/or foreign nucleic acids, in particular viral nucleic acids.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: April 24, 2018
    Inventors: Jens Gruber, Gabriele Jansen
  • Patent number: 9944907
    Abstract: The present disclosure relates to mutated genes of the LUX operon and their use in producing autoluminescent plants and bacteria exhibiting improved light output.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: April 17, 2018
    Assignee: BioGlow LLC
    Inventor: Alexander Krichevsky
  • Patent number: 9926574
    Abstract: The present invention relates to compositions and methods, in particular to methods based on systemic injection of rAAV, for delivering genes to cells of the central nervous system in mammals, such as brain neurons or glial cells, and in particular to motor neurons or glial cells of the spinal cord The invention also relates to methods of treating motor neuron disorders in mammals by expression of therapeutic genes. The invention stems from the unexpected discovery that peripheral injection of AAV vectors leads to a bypass of the blood brain barrier and a massive infection of motor neurons. The invention may be used in any mammal, including human subjects.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: March 27, 2018
    Assignees: GENETHON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventor: Martine Barkats